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Summary Clostridium difficile is the most common infectious cause of nosocomial healthcare-
associated diarrhea. The increasing prevalence of C difficile, spread in the community, virulence
and frequent relapse has created an urgent need to identify new effective treatments for
C. difficile infection. Among these, intravenous immunoglobulin (IVIG) is used for cases of severe
C. difficile infection. We undertook a systematic review to examine the published literature
pertaining to the use of immunoglobulin for C. difficile infection. Four retrospective studies and
five case reports that addressed the use of IVIG for the treatment of C. difficile infection were
identified. One study on the use of oral immunoglobulin was identified. Although overall there
appear to be benefits to using IVIG in recurrent severe disease, the small sample sizes and lack of
control groups in three of the four studies do not allow recommendations to be made regarding
the use of immunoglobulin in C. difficile infection. Further research is urgently needed to clarify
the role of immunoglobulin — intravenous or oral — for the treatment of C. difficile infection.
# 2009 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.Introduction
Clostridium difficile is the most common infectious cause of
healthcare-associated diarrhea, with an estimated incidence
ranging from 4 to 6 per 1000 admissions in endemic settings to
22.5 cases per 1000 admissions with the new epidemic
strain.1 Twenty to forty percent of hospitalized patients
may be colonized with this organism.2—4 C. difficile infection
(CDI) leads to prolonged hospitalization and costs,5—7 may be
associated with complications such as the need for colect-
omy,8,9 and has an attributable mortality ranging from 6% to
16%.10,11* Corresponding author.
E-mail address: ns2@medicine.wisc.edu (N. Safdar).
1201-9712/$36.00 # 2009 Published by Elsevier Ltd on behalf of Intern
doi:10.1016/j.ijid.2008.11.012The incidence and severity of CDI have been increasing in
the past decade, and a highly virulent epidemic strain,
producing a binary toxin, associated with considerable mor-
bidity and mortality has been reported.12,13
The treatment of CDI is challenging. Metronidazole
remains the first-line therapy, with oral metronidazole and
vancomycin reserved for severe cases. However, up to 30% of
patients with an initial episode of CDI will experience one or
more recurrences following cessation of the medication.14
A recently recognized major risk factor for developing CDI
is the presence of low serum antibody levels to C. difficile
toxin A.14,15 In a prospective cohort study of 271 hospitalized
patients, Kyne et al. found that patients who had serum IgG
antibody of 3.00 ELISA units or less were 48 times more likely
to get CDI.15 This observation provides the rationale for
studying immunoglobulin as a means of boosting humoralational Society for Infectious Diseases.
664 J. O’Horo, N. Safdarimmunity, thus preventing or ameliorating CDI. In recent
years, a handful of case reports and series have suggested
that intravenous immunoglobulin (IVIG) may be beneficial in
patients with severe CDI.16—25 We undertook a systematic
review to examine the available evidence regarding the role
of oral or intravenous immunoglobulin for the treatment of
CDI.
Methods
Articles were identified by PubMed searches performed on
April 2—5, 2008 and October 28—29, 2008 for the time period
1970—2008. Search terms were ‘CDAD’ (Clostridium difficile-
associated disease), ‘immunoglobulin’, ‘IVIG’, and ‘Clostri-
dium difficile’. Articles that investigated immunoglobulin
therapy for CDI in humans were included. No language
restrictions were applied. The references of relevant articles
were manually examined to identify additional studies.
Results
Three case series, one retrospective case—control study, and
five case reports were identified that examined IVIG therapy
for CDI (Tables 1 and 2). One study of oral immunoglobulin
therapy was identified.
In a case series of five pediatric hypogammaglobulinemic
patients with recurrent CDI, Leung et al. found that all five
treated with IVIG 400 mg/kg given once every three weeks
had complete resolution of symptoms. Patients required a
mean of two cycles of therapy before resolution of symp-
toms.21
Wilcox et al. performed a retrospective analysis of
patients treated with IVIG for CDI. Of 580 patients withTable 1 Studies examining the use of intravenous immunoglobu
Study Population
size
Controls Major comorbidities
Leung et
al., 1991
5 None Hypogammaglobulinemia
Wilcox et
al., 2004
5 None Comorbidities included
subarachnoid hemorrhage,
femoral neck fracture,
depression, CVA, and COPD
McPherson
et al., 2006
14 None Comorbidities included
pneumonia, stroke,
subarachnoid hemorrhage,
cellulitis, appendicitis,
diabetes, UTI, ARF, AML,
COPD, IHD, AF, lymphoma,
bladder cancer, parotitis,
sepsis, and pyelonephritis
Juang et
al., 2007
18 61 Not reported
AF, atrial fibrillation; AML, acute myeloblastic leukemia; ARF, acute rena
pulmonary disease; IHD, ischemic heart disease; IVIG, intravenous immrecurrent CDAD, five received immunoglobulin therapy. Dos-
ing ranged from 300 to 500 mg/kg and patients were given
from one to six doses. One patient had a complete response;
three patients had partial resolution of symptoms with IVIG
therapy, and one patient died without an apparent thera-
peutic response. Resolution typically occurred within 11 days
of the initiation of treatment.25
McPherson et al. conducted a retrospective analysis of 264
patients diagnosed with CDI. The study included 14 patients
receiving IVIG for recurrent CDI. Nine patients had a full
response, one had a partial response, and four patients
continued to worsen despite therapy. No patients experi-
enced complications attributable to IVIG therapy.22
Juang et al. conducted a retrospective analysis of 79
patients with severe CDI, comparing 18 patients who
received IVIG to a control group of 61 who did not. There
were no significant differences in the demographics or CDAD
severity scores in the patient groups. No significant differ-
ences were identified in terms of outcomes or severity of
symptoms after treatment.20
Hassett et al. reported a 49-year-old female with IgG1
deficiencywith nine episodes of CDI associatedwith colitis in
a two-year period, successfully treated with IVIG in combi-
nation with a probiotic agent. The patient had received
unsatisfactory treatment with various doses and combina-
tions of oral vancomycin, metronidazole, and rifampin. The
patient was given 1 g daily Saccharomyces boulardii for
probiotic therapy in combination with 30 grams every 2
weeks IVIG to treat the immune deficiency. The patient
had a symptom-free interval of 24months despite continued
antibiotic pressure from treatment for sinopulmonary infec-
tions. The authors concluded that in this immune deficient
patient, combining standard therapy with immunoglobulinlin for the treatment of Clostridium difficile infection
Dosage IVIG Study time
frame
Outcome
400 mg/kg every
three weeks
6 months All patients had full
resolution of symptoms
Ranged from 300
to 500 mg/kg
given as 1 to
6 doses
Retrospective
analysis from
2000 to 2002;
resolution
occurred
within 11 days
of initiation
of therapy
One patient had full
resolution of symptoms,
three had a partial
response, and one did
not respond to therapy
Ranged from 150
to 400 mg/kg
Retrospective
analysis from
2003 to 2005
Nine patients had full
resolution of symptoms,
one had a partial
response, and four did
not respond to therapy
400 mg/kg Retrospective
analysis from
2001 to 2003
No significant differences
in outcome were noted
between groups
l failure; CVA, cerebrovascular accident; COPD, chronic obstructive
unoglobulin; UTI, urinary tract infection.
Table 2 Case reports of intravenous immunoglobulin use in Clostridium difficile infection
Study Patient age/
gender
Major comorbidities Failed treatment regimens IVIG treatment regimen Follow-up Outcome
Hassett et
al., 1995
49 years/female IgG1 deficiency; recurrent
sinopulmonary infections
Metronidazole; vancomycin;
rifampin
30 g every two weeks, 1
gram Saccharomyces
boulardii daily
24 months Patient remained
asymptomatic for
2 years
Salcedo et
al., 1997
63 years/female Non-Hodgkin’s lymphoma Metronidazole; vancomycin 300 mg/kg IVIG once,
metronidazole,
vancomycin 10 days
further
Not stated Patient had recurrence 1
month later; successfully
treated with 10 days
metronidazole
64 years/male Large cell lung cancer Metronidazole; vancomycin 200 mg/kg IVIG once Not stated Patient improved within 24
hours; no recurrence
Beales, 2002 77 years/female COPD; NIDDM; pneumonia Metronidazole; vancomycin 400 mg/kg IVIG twice 21
days apart, vancomycin taper
10 months ‘Quick’ resolution followed
by patient remaining
symptom free throughout
follow-up
75 years/female COPD; NIDDM; pneumonia Metronidazole; vancomycin 400 mg/kg IVIG twice 21
days apart, vancomycin taper
8 months ‘Successful treatment’, no
recurrence in follow-up
69 years/male AAA Metronidazole; vancomycin 400 mg/kg IVIG twice 21
days apart, vancomycin taper
7 months ‘Resolved’, no recurrence
82 years/female CVA; pneumonia; PEG
site infection
Metronidazole; vancomycin 400 mg/kg IVIG twice 21
days apart, vancomycin taper
5 months ‘Resolved’, no recurrence
Murphy et
al., 2006
57 years/female CHF; Barrett’s esophagus; UTI Metronidazole; vancomycin,
Saccharomyces boulardii;
rifampin
400 mg/kg IVIG every day
for three days
4 months Patient remains toxin
positive but asymptomatic
Hassoun and
Ibrahim, 2007
72 years/male Hypothyroidism; Merkel cell
carcinoma; Non-Hodgkin’s
lymphoma, in remission
Metronidazole; vancomycin 400 mg/kg once with
vancomycin taper for 6 weeks
Not stated Improvement after 2
days; full resolution
by day 7
AAA, abdominal aortic aneurysm; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; IVIG, intravenous immunoglobulin; NIDDM, non-
insulin dependent diabetes mellitus; PEG, percutaneous endoscopic gastrostomy; UTI, urinary tract infection.
Im
m
u
n
o
glo
b
u
lin
fo
r
th
e
tre
atm
e
n
t
o
f
C
.
difficile
in
fe
ctio
n
665
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treatment alone.17
Salcedo et al. reported two patients with pseudomem-
branous colitis unresponsive to standard antibiotic therapy
with metronidazole and vancomycin. Patients were treated
with 200—300 mg/kg IVIG; both experienced resolution of
symptoms within 24—36 hours. Salcedo et al. tested nine
commonly used IVIG preparations for in vitro activity against
C. difficile toxin. All nine had toxin-neutralizing activity,
though the concentration varied by four-fold from the least
to the most active preparation.24
Beales published a reply to Kyne and Kelly’s therapeutics
update,26 which reported four cases of recurrent CDI suc-
cessfully treated with IVIG. Patients ranged in age from 69 to
82 years, and all had recurrence after two courses of metro-
nidazole and a vancomycin taper. IVIG 400 mg/kg was admi-
nistered twice, 21 days apart, while on a second vancomycin
taper. None of the patients had any further recurrences in the
5—10 months of follow-up. The author concluded that IVIG
appears to be a useful adjunct to vancomycin tapers in
refractory CDI.16
Murphy et al. offered the case report of a 57-year-old
female who developed recurrent CDI despite metronidazole
and vancomycin therapy. The patient was first given probiotic
therapy with S. boulardii; diarrhea briefly resolved, but
recurred a month later. Treatment was attempted with anion
exchange resins with minimal improvement. The patient was
given three treatments of IVIG 400 mg/kg, and had resolution
of diarrhea. The patient remained toxin-positive, but asymp-
tomatic through four months of follow-up.23
Hassoun and Ibrahim published a case report of a 72-year-
old male receiving chemotherapy who developed severe CDI.
After failing metronidazole/vancomycin treatment, the
patient was given a single dose of IVIG therapy 400 mg/kg
as well as a vancomycin taper. The patient improved by day 2,
resolving completely by day 7, with no further recurrence.18
Mattila et al. reported the first, and to-date, only, study
comparing orally administered immunoglobulin to standard
therapy. Thirty-eight patients with recurrent mild to mod-
erate recurrent CDI were randomized to receive C. difficile
immune whey (CDIW) or metronidazole. The study was
stopped prematurely due to the bankruptcy of the sponsor,
but preliminary results showed a comparable response
between the two therapies, with 100% response with metro-
nidazole compared to 89% in the CDIW group. After two
months of follow-up, 55% of patients in the metronidazole
arm had no recurrence compared to 56% in the CDIW arm.27
Discussion
Clostridium difficile infection is a growing public health
problem.28 There is an urgent need to develop new thera-
peutic approaches to treating CDI, including antibiotic-29 and
non-antibiotic-based therapies, such as probiotics,30 vac-
cines,31,32 and passive immunotherapy.33 In this review, we
have focused on examining the existing evidence for the use
of immunoglobulin for CDI. In our analysis we found that
there is a paucity of evidence to support the use of IVIG for
CDI. The preliminary studies that we identified suggest that
IVIG may be beneficial in cases of recurrent CDI, but defini-
tive recommendations are not possible with the currently
available literature. The only controlled study to-dateshowed no benefit of IVIG compared to the standard treat-
ment in patients with severe CDI; however, it should be noted
that this is the only study that aimed to use IVIG for ‘severe’
CDI; all other reports were treating ‘recurrent’ CDI. Current
treatment guidelines, which are several years old and under
revision, state that IVIG may be considered to prevent multi-
ple recurrences in patients severely affected with CDI.14
There are currently eight FDA approved IVIG products. The
products all vary slightly in method of preparation and final
IgA content. The FDA has approved IVIG for six clinical
indications, but over half of all IVIG prescribed is off-label.34
Antibodies against C. difficile toxin were detected in nine
commercial immunoglobulin preparations in an older study.
Titers of toxin-neutralizing antibody varied by a maximum of
a factor of four.24 In the studies we included in our analysis,
data on the levels of IgG to C. difficile toxin A in the blood
following IVIG treatment were not reported. Finally, it is
unclear how and if the IVIG enters the colon to exert its toxin
binding effect. Possibly, the active inflammation seen in
severe CDI allows for the exudation of some immune globulins
across the colonic mucosa.24
IVIG is prohibitively expensive and thus exploration of
other ways of providing passive immunotherapy is essential.
A promising area in immunoglobulin therapy for CDI is the use
of oral immunoglobulins. In an animal study, oral immuno-
globulin derived from eggs of immunized leghorn hens effec-
tively neutralized toxins A and B in a hamster model.35 A
human study using bovine immunoglobulin concentrate pre-
pared from colostral milk of cows immunized against toxin A
demonstrated that the antibody preparation retains the
ability to neutralize C. difficile toxin A after transit through
the stomach and small intestine.36 A safety study of immu-
noglobulin-containing whey protein concentrate prepared
from centrifuged milk of immunized cows showed no signifi-
cant side effects from oral treatment in severely ill patients
with CDAD.37 At this time, there has been only one study to
test oral immunoglobulin therapy in humans for efficacy. The
study was prematurely terminated, but the available data
showed oral immunoglobulin therapy to bewell tolerated and
approximately as effective as metronidazole. Research on
oral immunoglobulin therapy is needed to determine if it
represents a viable treatment option for recurrent CDAD.
In conclusion, further studies are urgently needed to
clarify the role of immunoglobulin treatment for CDI. Future
studies should measure IgG levels to toxin A and adjust
dosing accordingly with oral or intravenous immunoglobulin
treatment.
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